Cristina Ferrone

Chair

Cedars-Sinai Medical Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Background: Immune checkpoint inhibitors (ICIs) are increasingly used in gastrointestinal and liver cancers. However, antibiotic-induced gut microbiota disruption may influence ICI effectiveness. Objective: To evaluate association between antibiotic use and clinical outcomes among patients with gastrointestinal and liver cancers receiving ICI therapy. Methods: In this meta-analysis, we searched studies involving adults with gastrointestinal or liver cancers treated with ICIs, comparing outcomes between patients with and without antibiotic use. Eligible studies reported hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) for overall survival (OS), progression-free survival (PFS), objective response rate (ORR), or disease control rate (DCR). Random-effects models were used for pooled analyses. Results: 28 studies were included. Antibiotic use was associated with worse OS (HR 1.56; 95%CI: 1.23–1.98; I 2 =87.3%), PFS (HR 1.48; 95%CI: 1.15–1.90; I 2 =88.3%), and DCR (OR 0.55; 95%CI: 0.33–0.90, I 2 =65.0%), but no significant difference in ORR (OR 1.01; 95%CI: 0.78–1.31; I 2 =0%). Results were consistent in subgroup analyses by ICI type and timing of antibiotic administration. Antibiotic use was associated with worse OS and PFS in hepatocellular carcinoma (HR for OS: 1.49; 95%CI: 1.24–1.79; HR for PFS: 1.25; 95%CI: 1.01–1.56) and upper gastrointestinal cancers (HR for OS: 2.40; 95%CI: 1.48–3.90; HR for PFS: 2.15; 95%CI: 1.18–3.91), whereas colorectal cancer studies showed improved OS (HR: 0.58; 95%CI: 0.45–0.75). Conclusion: Antibiotic use is associated with worse outcomes in gastrointestinal or liver cancer patients receiving ICIs and should be carefully justified. Prospective studies are needed to validate these results.

Year:

2026

Biliary tract cancers (BTC) are aggressive malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we report integrative analysis of 63 BTC cell lines via multi-omics and genome-scale CRISPR screens. We identify widespread EGFR dependency in BTC, alongside dependencies selective to anatomic subtypes. Additionally, we delineate strategies to overcome therapeutic resistance, with combined EGFR inhibition potentiating targeting of KRAS -mutant and FGFR2 fusion–driven models and SHP2 inhibition effective in the latter context. Clustering RNA/protein expression and dependencies data revealed functional relationships transcending single-gene alterations, with biliary, squamous, or dual biliary/hepatocyte lineage signatures stratifying BTC models. These subtypes exhibit distinct dependency profiles—including cell fate transcription factors GRHL2 , TP63 , and HNF1B , respectively—and demonstrate prognostic significance in patient samples. Potential subtype-specific targetable vulnerabilities include integrinα3 and the detoxification enzyme UXS1 . This cell line atlas reveals therapeutic targets in molecularly defined BTCs, unveils disease subtypes, and provides a resource for therapeutic development. Significance: This integrative analysis of BTC cell lines defines the landscape of vulnerabilities across BTCs, stratifying distinct subtypes, and provides a key resource for studying disease heterogeneity. The findings highlight strategies for targeting BTCs with specific genomic alterations, as well as broader approaches based on shared molecular programs and essential pathways.

Year:

2025

Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute to resistance to CAR T-cell therapy in solid tumors, and appropriate model systems to identify and examine these factors using clinically relevant biospecimens are limited. In this study, we examined the activity of B7-H3–directed CAR T cells (B7-H3.CAR-T) using 3D microfluidic cultures of patient-derived organotypic tumor spheroids (PDOTS) and then confirmed the activity of B7-H3.CAR T cells in PDOTS. Although B7-H3 expression in PDOTS was associated with B7-H3.CAR-T sensitivity, mechanistic studies revealed dynamic upregulation of co-inhibitory receptors on CAR T-cells following target cell encounter that led to CAR T-cell dysfunction and limited efficacy against B7-H3–expressing tumors. PD-1 blockade restored CAR T-cell activity in monotypic and organotypic tumor spheroids with improved tumor control and upregulation of effector cytokines. Given the emerging role of TANK-binding kinase 1 (TBK1) as an immune evasion gene, we examined the effect of TBK1 inhibition on CAR T-cell efficacy. Similar to PD-1 blockade, TBK1 inhibition restored CAR T-cell activity in monotypic and organotypic tumor spheroids, prevented CAR T-cell dysfunction, and enhanced CAR T-cell proliferation. Inhibition or deletion of TBK1 also enhanced the sensitivity of cancer cells to immune-mediated killing. Taken together, our results demonstrate the feasibility and utility of ex vivo profiling of CAR T cells using PDOTS and suggest that targeting TBK1 could be used to enhance CAR T-cell efficacy by overcoming tumor-intrinsic and -extrinsic resistance mechanisms.

Year:

2025

Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute to resistance to CAR T-cell therapy in solid tumors, and appropriate model systems to identify and examine these factors using clinically relevant biospecimens are limited. In this study, we examined the activity of B7-H3–directed CAR T cells (B7-H3.CAR-T) using 3D microfluidic cultures of patient-derived organotypic tumor spheroids (PDOTS) and then confirmed the activity of B7-H3.CAR T cells in PDOTS. Although B7-H3 expression in PDOTS was associated with B7-H3.CAR-T sensitivity, mechanistic studies revealed dynamic upregulation of co-inhibitory receptors on CAR T-cells following target cell encounter that led to CAR T-cell dysfunction and limited efficacy against B7-H3–expressing tumors. PD-1 blockade restored CAR T-cell activity in monotypic and organotypic tumor spheroids with improved tumor control and upregulation of effector cytokines. Given the emerging role of TANK-binding kinase 1 (TBK1) as an immune evasion gene, we examined the effect of TBK1 inhibition on CAR T-cell efficacy. Similar to PD-1 blockade, TBK1 inhibition restored CAR T-cell activity in monotypic and organotypic tumor spheroids, prevented CAR T-cell dysfunction, and enhanced CAR T-cell proliferation. Inhibition or deletion of TBK1 also enhanced the sensitivity of cancer cells to immune-mediated killing. Taken together, our results demonstrate the feasibility and utility of ex vivo profiling of CAR T cells using PDOTS and suggest that targeting TBK1 could be used to enhance CAR T-cell efficacy by overcoming tumor-intrinsic and -extrinsic resistance mechanisms.

Year:

2025

Distinct fibroblast populations are associated with tissue types. A, UMAP projection based on the top five PCs of fibroblast single-cell transcriptomes. B, UMAP projections of single cells from each tissue type (colored) contributing to the fibroblast UMAP (gray). C, UMAP projections of single cells from autoimmune (left) and idiopathic (right) chronic pancreatitis samples (colored) contributing to the fibroblast UMAP (gray). D, Quantification of each fibroblast cluster within tissue types. E, Bubble plot demonstrating relative expression of marker genes across clusters. The intensity of the color is proportional to the average expression of the marker within a cluster, and the bubble size is proportional to the number of cells expressing the marker. F, Violin plots of the expression of genes with defined roles in fibroblast biology. G, Visualization of selected KEGG and Reactome pathways significantly enriched in fibroblast clusters. The bubble size is proportional to the number of genes enriched, and the intensity of the color is proportional to significance of the enrichment. Normal fibroblasts (F1); inflammatory fibroblasts (F2); injury-reactive fibroblasts (F3); transitional fibroblasts (F4); CAFs (F5). UMAP, UMAP, Uniform Manifold Approximation and Projection for Dimension Reduction.

Year:

2025

Integration of single-cell and spatial transcriptomics reveals spatially defined fibroblast populations. A, Marker gene expression for fibroblast clusters overlayed on untreated PDAC sample HTB2779. Black box corresponds to that in whole mount image in B . B, Whole mount image and progressively higher magnifications of H&E-stained section of HTB2779. Scale bars, 2 mm (left), 300 μm (middle), and 60 μm (right). The locations of histologically defined cancer glands are indicated by black arrows. C, Marker gene expression for fibroblast clusters overlayed on NAT-PDAC sample HTB2903. Black box corresponds to that in whole mount image in D . D, Whole mount image and progressively higher magnifications of H&E-stained section of HTB2903. Scale bars, 2 mm (left), 300 μm (middle), and 60 μm (right). The locations of histologically defined cancer glands are indicated by black arrows. H&E, hematoxylin and eosin.

Year:

2025

scRNA-seq of human pancreatic tissues. A, Schematic representation of the types of tissues employed in this study and the experimental pipeline for their analysis by scRNA-seq. B, UMAP visualization of single cells from all samples colored by cell type. C, UMAP projections of single cells from each tissue type (colored) contributing to the global UMAP (gray). D, Representative images of H&E-stained sections of each tissue type. Scale bar, 100 μm. E, Quantification of cell types within each tissue type. F, Quantification of cell populations (% from the total) along with the number of DE genes in each cell population between tissue types. UMAP, Uniform Manifold Approximation and Projection for Dimension Reduction; H&E, hematoxylin and eosin.

Year:

2024

Fibroblasts drive intercellular communication in the tumor microenvironment of PDAC. A, Aggregated cell–cell communication network in normal pancreas, pancreatitis, untreated PDAC, and NAT-PDAC samples showing the signaling (edges) sent from each cell population (nodes) inferred using CellChat. The edge weights between any two cell populations are scaled to reflect the total number of inferred interactions. All fibroblast cells are shown as one cell population, to depict the overall interactome driven by the fibroblast compartment as a totality. B, Comparison of incoming and outgoing signaling for different cell populations in each tissue type. C, Receptor–ligand interaction pairs regulating fibroblasts to epithelial cell communication. D, Visualization of inferred cellular communication between mesenchymal and ductal cell populations calculated based on the aggregated cell–cell communication network using CellChat. Each fibroblast subset is separated in this analysis to depict subset-specific interactions. E, Comparison of strengths of incoming and outgoing signaling in each fibroblast subset.

Year:

2024

Differentiation of fibroblasts is coupled with a loss of transcriptional regulatory programs. A, Trajectory analysis of fibroblast subclusters inferred by Slingshot. B, Gene expression of CAF marker genes plotted along the pseudotime trajectory leading to CAFs. Expression values in natural-log scale. C, RNA velocity analysis of fibroblast cells. D, Volcano plots of DE genes between fibroblast populations. Transcription factors that are DE between populations, with an adjusted P value 2 FC > 0.5 in absolute value, are indicated. E, Gene expression of selected transcription factors plotted along the pseudotime trajectory leading to CAFs. Expression values in natural-log scale. F, Top 20 candidate master regulators of transcriptional program altered between fibroblast populations identified by the master regulator analysis algorithm (MARINa). The targets of each transcription factor are shown in vertical bars (repressed genes are in blue, and activated genes in red) and are rank-sorted ( x -axis) from the one most downregulated to the one most upregulated in the selected conditions: normal fibroblasts compared with transitional fibroblasts and transitional compared with CAFs. The heatmaps on the right side of each panel indicate inferred differential activity (Act) and differential expression (Exp) of the transcription factor. MARINa, MAster Regulator INference algorithm.

Year:

2024

Genetic and transcriptomic features define distinct ductal cell populations. A, UMAP projection based on the top five PCs of ductal cell transcriptomes. B, Bubble plot demonstrating relative expression of marker genes across clusters. The intensity of the color is proportional to the average expression of the marker within a cluster, and the bubble size is proportional to the number of cells expressing the marker. C, Quantification of each cluster within tissue types. D, UMAP projections of KRAS mutation status in single cells. Subclustering of the ductal cell population is shown on the right. E, Violin plots indicating the expression of marker genes for cancer ( FXYD3 ), normal duct ( SLCA4 ), and hybrid ( CRISP3 , MUC5B , and SCGB3A1 ) cells in the three ductal cell clusters. Expression values in natural-log scale. F, Representative images of RNA-ISH (top) and H&E (bottom)-stained section tissue. Composition of RNA-ISH probe cocktails is indicated below. Normal pancreas was used to demonstrate staining of centroacinar cells/small duct (HTB2875) and centroacinar cell/large ducts (HTB2953). PDAC samples were used to demonstrate the staining of acinar-to-ductal metaplasia (HTB2903) and cancer cells (HTB2883). Scale bars, 100 μm for large images and 25 μm for inset images. UMAP, Uniform Manifold Approximation and Projection for Dimension Reduction; H&E, hematoxylin and eosin.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (22)

Russell Jenkins

Associate Professor

Medical University of South Carolina

UNITED STATES
View details

Michael Lawrence

Assistant Professor

Broad Institute

UNITED STATES
View details

Andrew Liss

Asssitant Professor

Harvard University

UNITED STATES
View details

Amit G. Singal

-

UNITED STATES
View details

Sandra Ryeom

Associate Professor/Associate Dean

Columbia University Irving Medical Center

UNITED STATES
View details

David J. Pinato

Imperial College London

UNITED KINGDOM
View details

Neehar D. Parikh

University of Michigan

UNITED STATES
View details

Genevieve Boland

Chair of Surgery

Medical College of Wisconsin

UNITED STATES
View details

Bruce Ksander

Associate Professor

Harvard Medical School

UNITED STATES
View details

Mari Mino-Kenudson

Pathologist

Massachusetts General Hospital

UNITED STATES
View details

William Sellers

Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Motaz Qadan

Hepatobiliary and Pancreatic Surgical Oncologist

Massachusetts General Hospital

UNITED STATES
View details

Kasper Lage

Group Leader

Broad Institute

UNITED STATES
View details

Srivatsan Raghavan

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Meng-Ju Wu

Assistant Professor

University of Massachusetts Chan Medical School

UNITED STATES
View details

Peter Sorger

Otto Krayer Professor of Systems Pharmacology

Harvard Medical School

UNITED STATES
View details

Gad Getz

Broad Institute

UNITED STATES
View details

Matthew Hall

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850

UNITED STATES
View details

Cyril Benes

Principal Investigator, Assistant in Genetics

Massachusetts General Hospital

UNITED STATES
View details

David Ting

Associate Professor of Medicine

-

UNITED STATES
View details

Tyler Laszewski

Senior Scientist

Novartis Institutes for BioMedical Research Inc

UNITED STATES
View details

Heiko Horn

European Bioinformatics Institute

UNITED KINGDOM
View details